Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic candidate to treat serious respiratory diseases, today announced the closing of a $103 million Series B financing. New investors RA Capital Management and Forge Life Science Partners led the financing, with participation from new investors EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital and existing investors, Atlas Venture, 5AM Ventures and Gimv.
Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for frevecitinib (KN-002). This novel inhaled dry powder therapeutic is in development for patients with asthma that remains inadequately controlled by standard of care inhaled maintenance therapies. These patients are typically prescribed medium-to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA), with or without additional controllers such as long-acting muscarinic antagonists (LAMA). Kinaset plans to begin a Phase 2b dose ranging trial in mid-2025.
Kinaset Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024 in San Francisco, CA. Members of Kinaset’s executive team are available for one-on-one investor and partner meetings.
Kinaset Therapeutics Appoints Christopher O’Brien, MD, PhD, FCCP, as Chief Medical Officer
Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, announced the appointment of Dr. Chris O’Brien as the Company's Chief Medical Officer.
Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients
Kinaset Therapeutics, a biopharmaceutical company developing a next generation anti-inflammatory therapy to treat patients with severe asthma, today announced that the first 24 participants have been dosed in its Phase 1b placebo-controlled study. This trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of KN-002, a novel and potent inhibitor of all Janus kinase (JAK) isoforms (i.e. JAK1, JAK2, JAK3, TYK2) that is formulated as a dry powder for inhaled delivery to the lung.
